India – Bharat Biotech willing to share Covaxin Code with other manufacturers
Amid the shortage of COVID-19 vaccines, especially the indigenously made Covaxin, the Centre and Hyderabad-based Bharat Biotech expressed willingness to let other companies produce the jab in a bid to ramp up vaccine production in the country.
During a media briefing, NITI Aayog member (Health), Dr VK Paul said, “People say that Covaxin should be given to other companies for manufacturing. I am happy to say that Bharat Biotech has welcomed this when we discussed it with them.”
The Centre, however, flagged the non-availability of a sophisticated laboratory with most vaccine makers that is necessary to produce the indigenously developed Covaxin jab.
The development comes a day after Delhi’s deputy chief minister, Manish Sisodia, said Bharat Biotech told the Delhi government that it could not provide ‘additional’ Covaxin doses to the national capital. Delhi has exhausted its stock of Covaxin because of which around 100 vaccination centres in 17 schools have been shut.
Covaxin was developed with seed strains received from the National Institute of Virology (NIV), and the phase 3 clinical trial was co-funded by the Indian Council of Medical Research (ICMR).